ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0354

How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Abstract Number: 0355

Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
Abstract Number: 0356

Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Abstract Number: 0357

Suppressing Inflammation Rather Than Lowering the Disease Activity Score Should Be Targeted During TNF Inhibitor Treatment to Slow Radiographic Changes in Patients with Ankylosing Spondylitis
Abstract Number: 0358

Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Abstract Number: 0359

Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 0360

Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
Abstract Number: 0361

Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration
Abstract Number: 0362

Patients with Psoriatic Arthritis Treated with Guselkumab Achieved Psoriasis-Related Symptom-Free State and Had No Skin Condition Impact on Their Health Related Quality of Life
Abstract Number: 0363

Efficacy of Ixekizumab on Disease Activity and Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status
Abstract Number: 0364

Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Abstract Number: 0365

Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Abstract Number: 0366

Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Abstract Number: 0367

Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
Abstract Number: 0368

Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].